ProTransit NanoTherapy

ProTransit NanoTherapy Overview

Founded 2013
Status Private
Employees 3
Latest Deal Type Grant (Announced)
Investors 4

ProTransit NanoTherapy General Information


Provider of a proprietary nanoparticle delivery system intended to treat conditions caused or related to free radical formation. The company's initial system is for skincare, where the application helps to reduce cellular and DNA damage caused by UV exposure, as well as helps to treat acute spinal cord injury, enabling physicians to treat their patients in an enhanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 16514 L Circle
  • Omaha, NE 68135
  • United States
+1 (608) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ProTransit NanoTherapy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 13-Aug-2018 00000 Announced Pre-Clinical Trials
2. Grant 08-Mar-2017 00.00 00000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 21-Nov-2014 $250K $250K Completed Pre-Clinical Trials

ProTransit NanoTherapy Executive Team (2)

Name Title Board Seat Contact Info
Gary Madsen Ph.D Co-Founder, President & Chief Executive Officer
Vinod Labhasetwar Ph.D Co-Founder

ProTransit NanoTherapy Investors (4)

To view ProTransit NanoTherapy‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
United States Department of Defense Government 000 0000 000000 0
Cleveland Clinic Innovations Corporate Venture Capital Minority 000 0000 000000 0
Invest Nebraska Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0

Ready to get started?

Request a free trial